Acceder

Threshold Pharmaceuticals, Inc (THLD): Opiniones

12,3K respuestas
Threshold Pharmaceuticals, Inc (THLD): Opiniones
2 suscriptores
Threshold Pharmaceuticals, Inc (THLD): Opiniones
Página
1.476 / 1.539
#11802

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

http://www.marketwatch.com/story/threshold-pharmaceuticals-announces-its-phase-3-trial-of-th-302-in-patients-with-advanced-soft-tissue-sarcoma-will-continue-as-planned-following-protocol-specified-interim-analysis-2014-09-22

Threshold Pharmaceuticals Announces Its Phase 3 Trial of TH-302 in Patients With Advanced Soft Tissue Sarcoma Will Continue as Planned Following Protocol-Specified Interim Analysis

Published: Sept 22, 2014 8:02 a.m. ET

................... anda que va bien >>> Pre-market: 4.21 -0.26 (-5.82%)

#11803

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

No indican los resultados obtenidos... Únicamente hacen mención a los mínimos a cumplir. A ver si el breve sabemos más.

#11805

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Pues vaya, no hay nada que rascar entonces. Seguiremos con el lateral de los últimos años.

#11806

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

yo entiendo que es un estudio "provisional",... quizás se pronuncien en unos dias no ??

#11807

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Threshold and its partner Merck KGaA, Darmstadt, Germany, have been and will remain blinded to the data from the trial. Based on projections derived from the interim analysis, Threshold is revising its guidance on timing for the number of events (deaths) required for the primary efficacy analysis. Previously, the Company projected the pre-specified number of events (n=434) would occur around the middle of 2015; the revised projections suggest the requisite events will occur in the latter half of 2015.

Brokers destacados